MGC Pharmaceuticals Ltd.

Notification of ASX Market Announcements

20 September 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that the following Announcements were released on the ASX Market Announcements Platform today.

·    Appendix 2A - Application for quotation of 17,923,153 Fully Paid Ordinary Shares issued as deferred purchase consideration in relation to the acquisition of MediCaNL Inc in April 2021 (Refer ASX announcement dated 22 April 2021).

A copy of the ASX Announcement (Appendix 2A) can be found at the following URL:

https://wcsecure.weblink.com.au/pdf/MXC/02423626.pdf 

·    Appendix 2A - Application for quotation of 300,000 Fully Paid Ordinary Shares issued on the exercise of 300,000 Employee Performance Rights

A copy of the ASX Announcement can be found at the following URL:

https://wcsecure.weblink.com.au/pdf/MXC/02423628.pdf 

·    Issue of a "Cleansing Notice" required under s708A(5)(e) of the Australian Corporations Act 2001 (Cth) in relation to the issue of the above shares.

A copy of the ASX Announcement can be found at the following URL:

https://wcsecure.weblink.com.au/pdf/MXC/02423633.pdf 

--Ends--

Authorised for release by the Executive Chairman, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma